Jim Birchenough
Stock Analyst at Wells Fargo
(1.26)
# 2,594
Out of 4,415 analysts
23
Total ratings
36%
Success rate
6%
Average return
Main Sectors:
Top Industries:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $2.69 | +11.52% | 4 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $55.07 | +27.11% | 2 | Feb 22, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $1 | $0.52 | +91.57% | 1 | Nov 6, 2023 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $3.08 | +1,198.70% | 1 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $9.00 | +433.33% | 2 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | n/a | $4.10 | - | 1 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | n/a | $1.40 | - | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | n/a | $125.59 | - | 2 | Feb 1, 2021 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $25.58 | - | 1 | Jul 7, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | n/a | $4.68 | - | 1 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | n/a | $937.61 | - | 1 | May 26, 2020 | |
| GILD Gilead Sciences | Downgrades: Equal-Weight | n/a | $65.33 | - | 3 | Apr 20, 2020 | |
| KZR Kezar Life Sciences | Maintains: Overweight | n/a | $0.85 | - | 1 | Mar 13, 2020 | |
| ARRY Array Technologies | Maintains: Outperform | n/a | $13.06 | - | 1 | Jun 28, 2018 | |
| ADAP Adaptimmune Therapeutics | Initiates: Market Perform | n/a | $1.19 | - | 1 | Mar 17, 2017 |
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.69
Upside: +11.52%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $55.07
Upside: +27.11%
Sangamo Therapeutics
Nov 6, 2023
Downgrades: Equal-Weight
Price Target: $1
Current: $0.52
Upside: +91.57%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $3.08
Upside: +1,198.70%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $9.00
Upside: +433.33%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: n/a
Current: $4.10
Upside: -
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.40
Upside: -
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $125.59
Upside: -
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $25.58
Upside: -
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $4.68
Upside: -
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: n/a
Current: $937.61
Upside: -
Gilead Sciences
Apr 20, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $65.33
Upside: -
Kezar Life Sciences
Mar 13, 2020
Maintains: Overweight
Price Target: n/a
Current: $0.85
Upside: -
Array Technologies
Jun 28, 2018
Maintains: Outperform
Price Target: n/a
Current: $13.06
Upside: -
Adaptimmune Therapeutics
Mar 17, 2017
Initiates: Market Perform
Price Target: n/a
Current: $1.19
Upside: -